Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1990 2
1996 2
1998 2
1999 4
2000 1
2001 5
2002 3
2003 3
2004 3
2005 1
2006 6
2007 4
2008 1
2009 4
2010 4
2011 4
2012 5
2013 5
2014 2
2015 4
2016 5
2017 1
2018 1
2019 3
2020 2
2021 5
2022 8
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Loriot Y, et al. Among authors: o hagan a. N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323. N Engl J Med. 2019. PMID: 31340094 Clinical Trial.
Flying Into Depression.
O'Hagan AD, Issartel J, Nevill A, Warrington G. O'Hagan AD, et al. Workplace Health Saf. 2017 Mar;65(3):109-117. doi: 10.1177/2165079916659506. Epub 2016 Sep 28. Workplace Health Saf. 2017. PMID: 27578874
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group. Siefker-Radtke AO, et al. Among authors: o hagan a. Lancet Oncol. 2022 Feb;23(2):248-258. doi: 10.1016/S1470-2045(21)00660-4. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030333 Clinical Trial.
Predictively consistent prior effective sample sizes.
Neuenschwander B, Weber S, Schmidli H, O'Hagan A. Neuenschwander B, et al. Among authors: o hagan a. Biometrics. 2020 Jun;76(2):578-587. doi: 10.1111/biom.13252. Epub 2020 Apr 6. Biometrics. 2020. PMID: 32142163
The probability of cost-effectiveness.
O'Hagan A, Stevens JW. O'Hagan A, et al. BMC Med Res Methodol. 2002;2:5. doi: 10.1186/1471-2288-2-5. Epub 2002 Mar 11. BMC Med Res Methodol. 2002. PMID: 11914138 Free PMC article.
86 results